TAZIDIME ADD-VANTAGE INJ 1.0GM/VIAL
TAZIDIME ADD-VANTAGE INJ 1.0GM/VIAL
Discontinued
DIN Number
00887129
Drug Class
Human
Market Date
Dec 31, 1991
Company
HC
eli lilly canada inc
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number00887129
AIG Number0116900004
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J01DD02 CEFTAZIDIME
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationIntravenous
AHFS Classification08:12.06.12
Health Canada Classification
ACTIVE INGREDIENTS (1)
CEFTAZIDIMEActive
Strength: 1 G / VIAL
Monograph: CEFTAZIDIME